Get it on Google Play

Tonix gets FDA alignment on Lyme disease antibody study design

August 3, 2026 7:00 AM EDT Send to a Friend
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) announced it has received official minutes from a Type C meeting with the U.S ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login